bioSyntagma

About:

bioSyntagma develops molecular fingerprint for diagnosing and discovering disease.

Top Investors: National Science Foundation, National Institutes of Health

Description:

BioSyntagma is a platform that generates a multi-omic, spatial cell profile to understand cancer in patients and provides an AI-based treatment plan. The company's contact modes are mail and physical address.

Total Funding Amount:

$1.38M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Phoenix, Arizona, United States

Founded Date:

2015-04-02

Contact Email:

info(AT)biosyntagma.com

Founders:

Colleen Ziegler, David Richardson, Dmitry Derkach

Number of Employees:

1-10

Last Funding Date:

2018-03-19

IPO Status:

Private

Industries: